MART-1:27-35 peptide vaccine

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC)

Conditions

Melanoma (Skin)Recurrent MelanomaStage IV Melanoma

Phase 1

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

CompletedNCT00091104

National Institutes of Health Clinical Center (CC)Melanoma (Skin)

Start: 2004-07-31End: 2010-10-31Target: 136Updated: 2012-03-15

Unknown Phase

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

CompletedNCT00006243

National Cancer Institute (NCI)Recurrent Melanoma, Stage IV Melanoma

Start: 2000-10-31Updated: 2013-01-25